Mind the Gap: A Global Disconnect Between Approved Antifibrotic Use and Off-label PH Therapies in PH-ILD

View the Poster

Read the Abstract

Research question: How do clinicians worldwide use approved antifibrotics compared with off-label pulmonary hypertension therapies in PH-ILD?
Key finding: Practice diverged substantially from approved indications across regions.
Why it matters: Patients with PH-ILD receive inconsistent care depending on where they are treated.
Conference and year: American Journal of Respiratory and Critical Care Medicine, 2026
Complete citation: Am J Respir Crit Care Med. 2026;212(Suppl 2). doi:10.1093/ajrccm/aamag286.296 (metadata to be verified)

Want the practical version of this research?